Bio Stock Based Compensation To Revenue from 2010 to 2024
| BPTH Stock | USD 0.77 0.03 3.75% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 24.65 | Current Value 44.96 | Quarterly Volatility 19.250115 |
Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Path's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77.9 K, Interest Expense of 31.2 K or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 472, Dividend Yield of 0.0 or PTB Ratio of 10.54. Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
Bio | Stock Based Compensation To Revenue |
Latest Bio Path's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Bio Path Holdings over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Bio Path's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Path's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Bio Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 41.36 | |
| Geometric Mean | 36.83 | |
| Coefficient Of Variation | 46.55 | |
| Mean Deviation | 18.17 | |
| Median | 44.96 | |
| Standard Deviation | 19.25 | |
| Sample Variance | 370.57 | |
| Range | 38.8753 | |
| R-Value | (0.75) | |
| Mean Square Error | 174.31 | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | (3.23) | |
| Total Sum of Squares | 5,188 |
Bio Stock Based Compensation To Revenue History
About Bio Path Financial Statements
Investors use fundamental indicators, such as Bio Path's Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Bio Path's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 24.65 | 44.96 |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out the analysis of Bio Path Correlation against competitors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.